API Intermediate Synthesis Process Control in Bulk Pharmaceutical Production serves a vital role within the pharmaceutical manufacturing sector. Identified by the CAS number provided, this intermediate is recognized for its critical involvement in the large-scale synthesis of active pharmaceutical ingredients. Its molecular attributes, including a specific formula and weight, ensure consistency and traceability throughout the production lifecycle. For unambiguous chemical identification, both the IUPAC name and InChIKey offer standardized references, aligning with best practices for chemical cataloging and regulatory dossiers. As an intermediate, this substance is formulated expressly for integration into complex, multi-step synthesis routes required in modern drug development and manufacturing.
From the perspective of physical and chemical specifications, this intermediate displays a characteristic set of physical properties relevant to robust process control in industrial settings. Key attributes, such as melting point, density, vapor pressure, and any available boiling point or flash point values, shape the handling guidelines and process protocols applied within bulk pharmaceutical factories. These intrinsic properties not only direct the practical aspects of storage and transport but also inform precise quality-control specifications essential for regulatory compliance.
The regulatory landscape governing API Intermediate Synthesis Process Control in Bulk Pharmaceutical Production is comprehensive and rigorous. The registration status under REACH, including the referenced article numbers and specified tonnage bands, is crucial for market access and compliance within the European Union. Similarly, inclusion on the TSCA inventory—alongside the relevant section references—asserts the substance’s compliance for commercial use in the United States. Where applicable, International Council for Harmonisation (ICH) guidelines are cited with full code and revision details, such as ICH Q3C(R8), as well as any specified impurity or residual solvent limits. Classification under the Globally Harmonized System (GHS) is outlined by listing all hazard statements and the prescribed signal word, which guides industrial hygiene and safety practices. Furthermore, references to pharmacopeia chapters highlight conformity with recognized pharmaceutical standards, while established OSHA permissible exposure limits and NIOSH recommended exposure limits are noted to ensure worker safety in occupational settings.
The applications of this intermediate are grounded in its pivotal function within the synthesis cascades of various active pharmaceutical ingredients. According to established use indices, it acts as a building block in multiple targeted drug manufacturing routes, contributing to the efficiency and output consistency of large-scale API production. Its value lies not in therapeutic efficacy but in enabling the reliable, compliant synthesis of downstream pharmaceutical compounds.
In terms of packaging and storage, this substance is supplied using the industry’s accepted standards, frequently available in 25-kilogram drums, 200-kilogram drums, and intermediate bulk containers suitable for integration into automated handling systems. Based on its stability features documented in the GHS analysis, storage recommendations call for a cool, dry environment, shielded from direct sunlight and incompatible materials, aligning with standard chemical stewardship protocols for this category. Shelf life expectations typically track the conservative norms for pharmaceutical intermediates, ensuring optimal quality retention during extended warehousing and shipment.
For further details and verification, reference sources include PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/{cid}), NIST WebBook (https://webbook.nist.gov/cgi/cbook.cgi?Name={cas_number}), the European Chemicals Agency (ECHA) database, and the US EPA TSCA inventory (https://www.epa.gov/tsca-inventory).
Related Articles
